Akanda

Akanda Equity Turnover

The Equity Turnover of Akanda (AKAN) as of Oct 25, 2026 is -0.02. In the previous year, Equity Turnover was 0.20 — a change of -112.23% (lower).

Equity Turnover

-0.02

YoY

-112.23%

Last updated:

Equity Turnover of Akanda is 2025 -0.02 . Equity Turnover of Akanda was 2024 0.20 . It decreases by -112.23% lower compared to the previous year.

The Akanda Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2020
-0.00 USD
Jan 1, 2021
-0.02 USD
Jan 1, 2022
0.10 USD
Jan 1, 2023
-0.56 USD
Jan 1, 2024
0.20 USD
Jan 1, 2025
-0.02 USD
The Akanda Equity Turnover history
YEAREquity TurnoverYoY
-0.02-112.23%
0.20-134.68%
-0.56-679.29%
0.10-617.45%
-0.02+4,492.71%
-0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Equity Turnover of Akanda is -0.02 in 2025.

Equity Turnover of Akanda changed from 0.20 to -0.02, representing a -112.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Akanda since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Akanda with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Akanda

All Key Metrics — Akanda